How to respond to CRISPR babies
By Editorial,
Nature
| 12. 05. 2018
People like to say that science is self-correcting. Events in China last week pose a serious challenge to that reassuring platitude. How do researchers respond to the failure of medical ethics, collective responsibility and professional standards that saw an immature experimental technique used to help produce human babies?
It has not yet been independently confirmed that the Chinese genome-editing researcher He Jiankui altered the DNA of embryos using a gene-editing technique and then implanted them in a woman, as he claims. Such a step would be significant and controversial because it would make a permanent change to the germ line that could be passed on to future generations. (This distinguishes germline editing from the use of gene-editing tools as therapies that correct genetic alterations in somatic cells in blood and other tissues.)
Verification of He’s claims could be difficult, given that privacy concerns rightly protect the identity of the parents and their one-month-old twin girls. But many scientists in the field agree on two things: the relative simplicity and widespread availability of the gene-editing tool CRISPR–Cas9 mean that what He...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...